local_hospital

Instytut Centrum Zdrowia Matki Polki

Address
lock Available on a paid plan

Endocrinology and Metabolic Disease Research

At Instytut Centrum Zdrowia Matki Polki in Lodz, clinical trials in hormonal diseases and nutritional and metabolic diseases focus on conditions such as type 2 diabetes, severe hypertriglyceridemia, familial chylomicronemia syndrome, and hyperlipidaemia. These studies are mainly designed to test new treatments and assess how well they control long-term metabolic risk.

  • Severe hypertriglyceridemia and familial chylomicronemia syndrome research aimed at lowering dangerous lipid levels
  • Type 2 diabetes and related metabolic risk management
  • Hypoparathyroidism and hypophosphatasia studies exploring symptom control and disease support

This work reflects a strong interest in improving treatment options for people with chronic metabolic and endocrine disorders.

Cardiovascular and Vascular Medicine

A major part of the research portfolio covers cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure, hypertension, non-obstructive hypertrophic cardiomyopathy, and inherited vascular conditions such as Marfan syndrome. The trials are focused on evaluating therapies that may reduce complications, improve heart function, and lower future cardiovascular events.

  • Atherosclerotic cardiovascular disease and prevention of major cardiac events
  • Heart failure and cardiomyopathy studies assessing symptom relief and function
  • Marfan syndrome and related aortic disease research in children and young adults

The site’s cardiovascular studies combine prevention, treatment effectiveness, and long-term safety research across both common and rare conditions.

Oncology and Hematologic Cancer Research

The clinic conducts extensive neoplasms research, especially in breast cancer, non-small cell lung cancer, small cell lung cancer, endometrial cancer, and colorectal cancer. These trials are generally aimed at testing new cancer therapies, improving response rates, and extending disease control in advanced or high-risk disease.

  • Breast cancer, including HER2-positive, triple-negative, and hormone receptor-positive disease
  • Non-small cell lung cancer and small cell lung cancer studies for advanced disease
  • Endometrial cancer, ovarian cancer, and other solid tumor research

Research at Instytut Centrum Zdrowia Matki Polki also includes studies in lymphomas and other difficult-to-treat cancers, with a strong emphasis on better outcomes for patients with limited treatment options.

Pediatric and Rare Disease Studies

A distinctive feature of this site is its work in congenital, hereditary, and neonatal diseases and other rare disorders. Trials include Marfan syndrome, spinal muscular atrophy, Angelman syndrome, Dravet syndrome, and tuberous sclerosis complex. The overall aim is to improve care for children and families living with uncommon and often serious conditions.

  • Spinal muscular atrophy and pediatric multiple sclerosis research
  • Marfan syndrome and other inherited connective tissue disorders
  • Rare genetic diseases such as Angelman syndrome and Dravet syndrome

These studies often explore whether emerging therapies can slow disease progression, improve function, or provide more durable symptom control in young patients.

Kidney, Immune, and Digestive System Research

The research program also spans immune system diseases, digestive system diseases, and hemic and lymphatic diseases. Key conditions include ulcerative colitis, Crohn's disease, chronic kidney disease, nephrotic syndrome, and atypical hemolytic uremic syndrome. These studies are designed to improve disease control, protect organ function, and evaluate longer-term treatment safety.

  • Ulcerative colitis and Crohn's disease treatment research in children and adults
  • Chronic kidney disease with proteinuria and iron deficiency anemia
  • Atypical hemolytic uremic syndrome and other immune-mediated conditions

Across these areas, the site supports trials that aim to improve symptom remission, reduce complications, and strengthen long-term disease management.

Neurology, Eye Disease, and Maternal-Fetal Research

Additional trials address nervous system diseases, eye diseases, and selected pathological conditions. Research includes multiple sclerosis, epilepsy, thyroid eye disease, and pregnancy-related conditions such as hemolytic disease of the fetus and newborn. The purpose of these studies is to improve safety, control symptoms, and support better outcomes for both patients and newborns.

  • Multiple sclerosis and epilepsy studies in pediatric and adult populations
  • Thyroid eye disease research focused on disease activity and function
  • Hemolytic disease of the fetus and newborn trials aimed at protecting fetal and neonatal health

This broad portfolio shows the site’s commitment to both complex chronic disease research and specialized care for vulnerable patient groups.

Site Overview

assignment
148
connected trials
corporate_fare
73
sponsors
science
203
IMPs

Activity Indicator

Last 6 months

14
Trials started
-30% vs previous period.
20
Trials started 6–12 months ago
148
Total trials linked
Highly Active
trending_downDeclining-30%
4
2
2
4
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 18 therapeutic areas and 15 of 203 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 195 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
90
Sponsors (total)
73
Active sponsors
55

Sponsor Network

Top 55 by active trials.

lock +54 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +26 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
148
Outperforms 99% of sites
public
Therapeutic diversity
18areas
Outperforms 99% of sites
groups
Sponsor diversity
73sponsors
Outperforms 99% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Instytut Centrum Zdrowia Matki Polki

lock Showing 1 of 148 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI)Bayer AGPhase IIINot Yet RecruitingOct 2023Nov 2024

IMP list

lock Showing 1 of 203 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Carboplatin21Unknown2021-06-012026-06-23

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.